BioSpace News Archive

Millions of Canadians are doing their part to help prevent the spread of COVID-19 by downloading and using the COVID Alert app.

- LIPAC Oncology LLC and Huons Co., Ltd. today announced the achievement of a major development milestone in their partnering agreement by finalizing its Clinical Study Report for a Phase 2A marker lesion clinical trial in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC) trea

First Nation Group is pleased to announce a new partnership with NightWare, the creators of the NightWareTM therapeutic platform, to deliver innovative care to our nation’s heroes diagnosed and struggling with severe nightmares associated with post-traumatic stress disorder (PTSD) or nightmare disorder.

Specialty cancer diagnostics company Precipio, Inc. has entered into an agreement with a major US-based oncology distributor to offer Precipio’s HemeScreen POL program to its independent community oncology practices nationwide.

Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia.

Summus Medical Laser, the leader in Class IV Therapeutic Lasers, today announced the company has been selected as a Top 5 Innovator by Guided Solutions with their international debut of The Horizon Laser System at COMPAMED/MEDICA 2020.

Emmaus Life Sciences, Inc., a leader in the treatment of sickle cell disease, announced that it was notified by the Michigan Department of Health and Human Services that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the " Company " or " GenSight "), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP

Since 2010, health plan has reduced greenhouse emissions by 34%, paper use by 63%, waste sent to landfills by 40%

Xenetic Biosciences, Inc. announced that it has entered into a securities purchase agreement with several institutional and accredited investors providing for the purchase and sale of 2,448,980 shares of the Company’s common stock at a purchase price of $2.45 per share, in a registered direct offering priced at-the-market under Nasdaq rules.